In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model

Ítems similars

• Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy
  per: Blattmann, Claudia, et al.
  Publicat: (2015)
• Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines
  per: Oertel, Susanne, et al.
  Publicat: (2011)
• The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Alleviates Salinity Stress in Cassava
  per: Patanun, Onsaya, et al.
  Publicat: (2017)
• The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma
  per: Ghayad, Sandra E., et al.
  Publicat: (2018)
• The inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidation
  per: Samuni, Yuval, et al.
  Publicat: (2009)